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Objective: Hypertension frequently occurs during the immediate postoper-
ative period in children after repair of aortic coarctation but may also occur
after repair of other congenital heart defects. Nitroprusside has often been
used to control blood pressure in this setting. Because hypertension after
coarctation repair is frequently associated with elevations in cat-
echolamines, esmolol, a short-acting b-blocking agent, may be an effective
alternative. Therefore we undertook the first systematic investigation to
determine the efficacy and disposition of esmolol in pediatric patients with
acute hypertension after cardiac operations. Methods: Twenty patients aged
1 month to 12 years (median 25.6 months) with acute hypertension after
cardiac operations received esmolol in an opened-labeled trial. Esmolol was
titrated to a blood pressure less than or equal to the 90th percentile for age.
Results: Ten patients had coarctation repair and the remaining patients
underwent repair of other congenital heart defects. On final esmolol dose
(mean 6 standard deviation dosage 700 6 232 mg/kg/min) there was a
significant percent decrease in heart rate and systolic and diastolic blood
pressures from postoperative values. Esmolol dose was significantly asso-
ciated with percent reduction in systolic blood pressure. Final esmolol dose
and total body clearance were significantly higher in patients after coarc-
tation repair. There were significant associations between esmolol dose and
esmolol blood concentrations at steady state. Conclusions: The dosage
required to control hypertension in patients after repair of aortic coarcta-
tion was higher than patients who underwent repair of other congenital
heart defects. Esmolol was effective in controlling blood pressure in 19 of 20
patients without adverse effects. (J Thorac Cardiovasc Surg 1998;115:890-7)
Acute postoperative hypertension occurs in 37%to 100% of patients after aortic coarctation
repair1, 2 but may occur after repair of other con-
genital heart defects.3-5 Sodium nitroprusside is
frequently used to manage hypertension after car-
diac operations because of its ease of titration and
its rapid onset and offset of action. However, sodium
nitroprusside is an indirect stimulator of the sympa-
thetic nervous system.6, 7 This may further aggravate
the increased sympathetic activity frequently present
in patients who have had repair of aortic coarcta-
tion.1, 8 In some cases nitroprusside may add to the
tachycardia decreasing arterial oxygen saturation
tension (PaO2) and oxygen saturation.
9 b-Adrener-
gic blockade would provide rational therapy in this
setting but has been limited by the lack of a titrat-
able intravenous agent that had a rapid onset and
offset of action.
Esmolol is an intravenous, cardioselective, b-ad-
renoceptor antagonist with a short duration of ac-
tion.10, 11 It is easily titratable and has safely been
applied in the critical care setting, where potential
adverse effects (e.g., bradycardia, hypotension, or
bronchospasm) can be rapidly reversed.12 In adults,
esmolol has been used for the acute management of
supraventricular arrhythmias,13 ischemic heart dis-
ease,14 intraoperative and postoperative hyperten-
sion,15, 9 and in other situations where brief adren-
ergic blockade is required.16, 17 Esmolol has been
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shown to effectively attenuate the hemodynamic
responses associated with stressful stimuli (e.g., en-
dotracheal intubation) in the perioperative peri-
od.15, 18 Although the effects of esmolol are well
characterized in adults, little information is known
concerning its effects in children.19-21 On the basis of
esmolol’s pharmacologic profile, it may be a suitable
alternative to sodium nitroprusside for the manage-
ment of acute cardiac postoperative hypertension in
pediatric patients. To date, trials evaluating esmolol
as the sole agent in this clinical setting are lacking.
Specifically, the goals of this investigation were to
(1) determine the dosing requirements and efficacy
of esmolol in managing cardiac postoperative hyper-
tension; (2) determine any associations between
esmolol dose or blood concentration and hemody-
namic parameters; and (3) determine the pharma-
cokinetic parameter estimates of esmolol in chil-
dren.
Methods
The protocol was approved by the Institutional Review
Board for Human Research. Written informed consent
for participation was obtained from the patients’ parents
or legal guardians. Patients who had cardiac operations,
from birth (term newborn) to 12 years of age, were
considered for study enrollment if they had significant
hypertension or were receiving sodium nitroprusside as an
antihypertensive agent during the immediate postopera-
tive period. Significant hypertension was defined as a
blood pressure greater than the 95th percentile for age22
(Table I) on three or more consecutive arterial blood
pressure recordings. For those patients receiving nitro-
prusside, the dose was weaned or discontinued and blood
pressure assessed for 10 minutes or less. Other inclusion
criteria were (1) an indwelling arterial catheter for esmo-
lol blood sampling and continuous blood pressure monitor-
ing and (2) an indwelling venous catheter for esmolol
administration. A Spacelabs Monitor (model 90342;
Spacelabs Inc., Redmond, Wash.) continuously displayed the
electrocardiogram through lead V2 or V5, heart rate (HR),
respiratory rate, systolic blood pressure (SBP), diastolic
blood pressure (DBP), and mean arterial blood pressure
(MAP). Patients with pulmonary disease, congestive heart
failure, diabetes mellitus, hypoglycemia, receiving inotropic
agents, or any antihypertensive agent other than sodium
nitroprusside were excluded from the study.
Antihypertensive and antiarrhythmic medications were
discontinued the day before the operation. Three or four
preoperative HRs and blood pressures were obtained
during the day before the operation and the mean deter-
mined for patients entering the study. Blood pressures
were measured using a Dinemapp oscillometric blood
pressure recorder (Critikon, Inc., Tampa, Fla.) applying
standard techniques with patients in the supine or sitting
position depending on patient age.22 Before the opera-
tion, a complete blood count with differential and serum
electrolyte profile was obtained. Postoperative manage-
ment was not influenced by the protocol. Standard seda-
tion and analgesia management was morphine, 0.1 mg/kg
intravenously every 1 hour, and lorazepam, 0.1 mg/kg
intravenously every 6 hours as needed.
Esmolol (10 or 20 mg/mL) was prepared in dextrose 5%
water23 and administered intravenously by continuous
infusion using a syringe pump (model 2001, Medfusion
Inc., Duluth, Ga.). Esmolol dose was based on the patient
age (Table II) and titrated until blood pressure was equal
to or less than the 90th percentile for age (Table I) or 1000
mg/kg/min was achieved. During esmolol infusion, arterial
blood pressure and HR were recorded every 1 to 3
minutes depending on how rapidly these parameters were
changing. MAP was calculated using the following equa-
tion:
MAP 5
~SBP – DBP!
3
1 DBP
The final dose was maintained for 30 minutes to ensure
steady-state conditions19 and then discontinued. Blood
pressure and HR monitoring continued for 30 minutes
after stopping esmolol. Esmolol or nitroprusside was
restarted after the protocol was completed if clinically
indicated.
Esmolol blood samples (1.2 ml) were obtained at the
following times: (1) just before starting the infusion; (2)
before two dosage adjustments maintained for 20 minutes
or longer; (3) at final dose; (4) just before stopping the
Table I. Blood pressure (mm Hg) values for entry
criteria and esmolol dosing threshold
Age
Significant
hypertension
(95th%)*
Severe
hypertension
(99th%)
Normal blood
pressure
(#90th%)†
Newborn SBP $ 96 SBP $ 106 SBP # 87
7-30 days SBP $ 104 SBP $ 110 SBP # 101
,2 yr SBP $ 112 SBP $ 118 SBP # 105
DBP $ 74 DBP $ 82 DBP # 68
3-5 yr SBP $ 116 SBP $ 124 SBP # 107
DBP $ 76 DBP $ 84 DBP # 68
6-9 yr SBP $ 122 SBP $ 130 SBP # 111
DBP $ 78 DBP $ 86 DBP # 70
10-12 yr SBP $ 126 SBP $ 134 SBP # 117
DBP $ 82 DBP $ 90 DBP # 75
SBP, Systolic blood pressure; DBP, diastolic blood pressure. Adapted from
reference 22.
*Entry criteria for blood pressure.
†Esmolol dosing threshold or maximum of 1000 mg/kg/min.
Table II. Esmolol dosing guidelines
Age
Dose* (mg/kg/min)
Starting Titrating
0-7 days 50 25-50 every 20 min
8 days to 1 mo 75 50 every 20 min
.1 mo to 1 yr 100 50 every 10 min
.1 yr to 12 yr 150 50-100 every 10 min
*Maximum dose: 1000 mg/kg/min.
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infusion; and (5) at 2, 4, 6, and 10 minutes after stopping
the infusion. Blood samples were obtained through an
arterial line and immediately placed in test tubes contain-
ing sodium fluoride to prevent in vitro conversion of
esmolol to its metabolite (ASL-8123).24 A 1.0 ml aliquot
was transferred to a test tube containing 3 ml of acetoni-
trile and the internal standard. Samples were vortexed and
cold centrifuged (4000 rpm) for 10 minutes. The superna-
tant containing esmolol was extracted, placed on ice, and
stored at –20° C until analysis.
Esmolol blood samples were analyzed by high-perfor-
mance liquid chromatography using a similar technique as
previously described.25 The limit of sensitivity was 0.10
mg/ml. Standard curves were linear and reproducible over
the range of 0.10 to 10 mg/ml (correlation coefficients .
0.99). The mean 6 SD interday and intraday coefficients
of variation for the assay were 4.86% 6 2.13% and 3.25%
6 1.77%, respectively.
Blood esmolol concentration–time profiles were ana-
lyzed by noncompartmental pharmacokinetics. The termi-
nal elimination half-life (t1/2) was determined from the
slope of the terminal elimination phase. Total body clear-
ance (TBC) was calculated by the following equation:
TBC 5 K
8
/Css
where K° was the final dose and Css was the mean of
concentrations obtained at steady state. The volume of
distribution at steady state (Vdss) was determined by
dividing the elimination rate constant (Ke 5 0.693/t1/2)
into TBC.26
Statistical analysis. Baseline hemodynamic parame-
ters were defined as the three consecutive measure-
ments of blood pressures and HRs obtained the day
before the operation. Percent change in hemodynamic
measurements during the postoperative period and at
final dose were determined from baseline values. Sig-
nificant differences were determined using a paired t
test. A Student’s t test was used to determine significant
differences between the group that underwent coarcta-
tion repair and those that underwent repair of other
congenital heart defects for (1) mean TBC, (2) mean
final dose, (3) mean steady-state esmolol blood concen-
trations at final dose, and (4) mean percent change in
hemodynamic parameters during the postoperative pe-
riod and on final esmolol dose.
Stepwise multiple regression analysis, using forward
addition and backward elimination, was used to determine
the association between esmolol dose and the mean
percent change of measured hemodynamic parameters.
The mean percent change in hemodynamic parameters
Table III. Demographic data
Patient
Age
(mo) Sex/race
Weight
(kg)
BSA
(m2) Diag.
HR*
(BPM)
SBP/DBP
(mm Hg)
MED.
PTA†
1 5.2 F/B 3.1 0.20 ASD/VSD 126 81/58 Capt
Furo
2 18.0 F/W 8.1 0.40 VSD/DCRV 123 102/54 Capt
3 24.2 M/W 12.0 0.53 CoA 108 116/64‡ Capt
4 8.4 M/B 8.0 0.36 CoA/PDA 109 111/54 Capt
5 36.0 M/B 11.5 0.53 TOF/Down’s 112 107/52
6 148.0 F/B 46.8 1.38 Ao Sten 88 113/61
7 35.0 F/B 13.3 0.60 CoA 112 120/69‡
8 1.2 M/B 3.7 0.23 Dup Ao Ar 180 95/53
9 55.0 F/W 17.2 0.72 CoA 86 117/54‡
10 2.4 M/W 6.2 0.30 CoA 127 153/79§
11 55.0 F/B 22.0 0.83 CoA 90 127/68§ Aten
12 75.0 M/B 22.5 0.89 VSD 81 103/51
13 32.0 F/B 12.7 0.55 ASD 103 106/45
14 61.6 M/W 17.9 0.73 ASD 102 107/60
15 21.5 F/W 10.0 0.44 CoA/PDA 129 114/62‡ Capt
16 1.0 M/W 1.8 0.15 CoA/PDA 145 99/54 Capt
17 15.5 M/W 13.2 0.53 CoA 118 107/57
18 58.0 F/W 16.8 0.70 CoA 117 115/76
19 27.0 M/B 12.8 0.58 VSD/PDA 113 126/70§ Dig
Furo
20 16.4 M/B 9.2 0.41 VSD 105 104/43
Mean 6 SD 34.8 6 34.6 13.4 6 9.7 0.55 6 0.28
BSA, Body surface area; F, female; M, male; B, black; W, white; ASD/VSD, atrial septal defect/ventricular septal defect; DCRV, double-chambered right
ventricular; CoA, coarctation of the aorta; PDA, patent ductus arteriosus; TOF/Down’s, tetralogy of Fallot/Down syndrome; Ao Sten, aortic stenosis; Dup Ao
Ar, duplicate aortic arch.
*HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure reported as mean of three consecutive preoperative measurements.
†PTA, Before admission; Capt, captopril; Furo, furosemide; Aten, atenolol; Dig, digoxin.
‡Significant hypertension (n 5 4) (see Table I).
§Severe hypertension (n 5 3) (see Table I).
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(i.e., HR, SBP, DBP, and MAP) for all patients receiving
the same dose, under steady-state conditions, was deter-
mined from a minimum of three measurements for each
parameter. Steady state was defined as maintaining the
same dose for 20 minutes or more. Least squares regres-
sion analysis was used to examine associations between
the following: (1) patient age and pharmacokinetic param-
eters (TBC, t1/2, and Vdss), (2) mean esmolol blood
concentration and mean percent reduction in hemody-
namic parameters for all patients on the same dose under
steady-state conditions, and (3) dose and mean esmolol
blood concentrations at steady state. Significance was
defined as a 5 0.05.
Results
Twenty patients aged 1 month to 12 years
(median 25.6 months) were enrolled in this inves-
tigation. Patient characteristics are described in
Table III. Ten patients underwent repair of aortic
coarctation. The remaining patients had repair of
other congenital heart defects. Seven patients had
preoperative hypertension (6, coarctation repair;
1, ventricular septal defect/patent ductus arterio-
sus) (Table III). Postoperatively, 12 (6, aortic
coarctation) patients had systolic hypertension, 1
patient had diastolic hypertension, and the re-
mainder had both. Seventeen patients had severe
hypertension (.99th percentile for age) and three
patients had significant hypertension (.95th per-
centile for age) (Table IV). Mean time from
completion of the operative procedure to study
entry was 4.7 hours (range 2.0 to 9.5 hours).
Eighteen patients were receiving nitroprusside
(mean dose 3.5 mg/kg/min; range 1 to 7 mg/kg/
min) during the immediate postoperative period.
Nitroprusside was discontinued and esmolol was
begun in 17 patients. In the remaining patient
(patient 11), nitroprusside was discontinued after
achieving an esmolol dose of 700 mg/kg/min. The
mean esmolol dose required to normalize blood
pressure was 700 mg/kg/min (range 300 to 1000
mg/kg/min). Final esmolol dose requirements in
patients undergoing coarctation repair (mean
dose 6 SD: 830 6 153 mg/kg/min; 18,608 6 4,905
mg/m2/min) was significantly (p 5 0.01) higher
than patients having repair of other congenital
heart defects (mean dose 6 SD: 570 6 230
mg/kg/min; 12,766 6 5,559 mg/m2/min). No signif-
Table IV. Postoperative and final hemodynamic results
Patient
Postoperative Final After/esmolol*
HR
(beats/min)
SBP/DBP
(mm Hg)
%HTN
SBP/DBP
HR
(beats/min)
SBP/DBP
(mm Hg)
%HTN
SBP/DBP
Esmolol
(mg/kg/min)
HR
(beats/min)
SBP/DBP
(mm Hg)
1 126 131/84† 17/14 126 99/57 212/223 500 126 121/68
2 135 143/81† 28/10 136 98/62 213/216 550 130 104/59
3 122 147/68† 31/28 111 109/53 23/228 950 123 133/74
4 133 127/60† 13/219 134 102/61 29/218 950 126 115/50
5 115 110/82‡ 25/8 112 90/63 222/217 300 111 94/61
6 129 146/81† 16/21 114 102/70 219/215 300 118 130/82
7 140 144/93† 26/22 114 110/71 25/27 950 130 147/103
8 192 125/62† 12/216 148 96/49 214/234 350 159 101/47
9 116 132/74† 14/23 111 94/59 219/222 850 123 105/60
10 133 136/85† 21/12 124 118/66 1/211† 1000 129 131/68
11 92 129/70† 11/28 121 102/52 212/32 950 130 110/51
12 105 128/74‡ 5/25 113 108/77 212/1 500 111 118/82
13 153 131/73† 13/24 125 106/64 25/214 700 134 129/74
14 115 124/67† 7/212 102 100/59 214/222 800 108 119/71
15 150 120/72† 7/23 120 102/60 29/219 750 131 108/60
16 165 111/79† 7/NA§ 125 92/58 212/NA§ 600 155 100/65
17 159 118/75† 5/1 130 105/69 26/27 650 140 110/67
18 118 118/68‡ 2/211 107 105/66 210/213 650 116 112/70
19 129 126/65† 13/212 117 94/52 216/230 1000 119 112/61
20 122 139/85† 24/15 116 95/58 215/222 700 119 117/59
Mean 6 SD 13 6 9/21 6 12 211 6 6/218 6 9 700 6 232
HR, Heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; %HTN, percent hypertension based on 95th percentile for age.
*Mean of three to four consecutive measurements immediately after esmolol.
†Severe hypertension (see Table I).
‡Significant hypertension (see Table I).
§NA, Not available.
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icant difference was found in steady-state esmolol
blood concentrations at final dose between these
groups.
The pharmacokinetic parameter estimates for all
patients were (mean 6 SD): Vdss (L/kg) 5 0.53 6
0.33; TBC (ml/kg/min) 5 126 6 37; t1/2 (min) 5
2.7 6 1.3. Patient age and pharmacokinetic param-
eters Vdss and t1/2 were not significantly associated
(r2 5 0.18, p 5 0.07; r2 5 0.06, p 5 0.28, respective-
ly). A weak but significant inverse association was
found between age and TBC in ml/kg/min (r2 5 0.28,
p 5 0.02). A significant association was found
between esmolol dose in both mg/m2/min (Fig. 1)
and mg/kg/min (mg/kg/min 5 143.9 1 89.5 3 blood
concentration; r2 5 0.63; p 5 0.001) and esmolol
blood concentrations at steady state. TBC (ml/m2/
min) in patients undergoing coarctation repair
(mean 6 SD: TBC 5 3271 6 835) was significantly
(p 5 0.006) higher than in patients having repair of
other congenital heart defects (mean 6 SD: TBC 5
2396 6 571); TBC in ml/kg/min approached signif-
icance (p 5 0.076) between these groups.
A significant percent increase in postoperative
hemodynamic measurements was found when com-
pared with baseline values. On final esmolol dose a
significant percent reduction (p # 0.005) (Fig. 2) in
HR and blood pressure was noted from postopera-
tive values. Percent change between baseline and
final hemodynamic measurements was significant
for SBP (p 5 0.001) (Fig. 2). A smaller percent
decrease was found in SBP on final esmolol dose in
patients who underwent coarctation repair than
patients having repair of other congenital heart
defects (28.5% vs 214.2%; p 5 0.001, respectively).
No other significant differences were found in he-
modynamic measurements between these groups.
By multiple stepwise regression analysis, esmolol
dose was only significantly associated with percent
change in SBP (Fig. 3).
The mean time to normalize blood pressure was
1.65 hours (range 0.6 to 3.6 hours). One patient
(patient 10) did not achieve an SBP at the 90th
percentile or less for age with an esmolol dose of
1000 mg/kg/min.
Hemodynamic measurements (SBP, DBP, and
HR) were significantly (p # 0.02) elevated after
discontinuation of esmolol when compared with
final esmolol dose values. Eight patients received
one to three doses of morphine during the protocol
(number of doses: 1 [n 5 6], 2 [n 5 1], and 3 [n 5
1]). Four patients received one dose of lorazepam
whereas two patients received one dose of loraz-
epam and morphine. Ten patients were restarted on
esmolol within 10 to 17 minutes of the conclusion of
the study. For two patients, esmolol was restarted at
1 and 2 hours. Esmolol was continued for 6 to 48
Fig. 1. Scatterplot showing the association between esmolol dose and blood concentration at steady state,
as well as the predicted blood concentration by dose (solid line) and 95% confidence limits (dashed lines).
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hours. Four patients were started on an angiotensin-
converting enzyme inhibitor and the remainder were
placed on nitroprusside after the study. No adverse
effects were associated with esmolol.
Discussion
Acute postoperative hypertension occurs in 37%
to 100% of patients after aortic coarctation repair1, 2
but may occur after repair of other congenital heart
defects.3-5 The pathogenesis of paradoxic hyperten-
sion after coarctation repair involves the activation
of the sympathetic nervous system (first phase) and
renin-angiotensin system (second phase). In the first
phase, postoperative norepinephrine concentrations
have been found to increase 750% within 12 hours,
leading predominantly to a rise in SBP.1, 8 In the
second phase, plasma renin activity increases 24 to
72 hours postoperatively producing significant ele-
vations in DBP.1 This phase may be prematurely
activated when hypertension is controlled by sodium
nitroprusside. Renin levels have been shown to
increase fivefold within 30 minutes of induction of
hypotension with sodium nitroprusside.6 The result-
ing increased angiotensin II vasoconstrictive activity
would also increase sympathetic outflow from the
adrenal glands and central nervous system.7 Consid-
ering these physiologic changes a b-blocker, such as
esmolol, should have a major influence on some of
the cardiovascular changes after coartectomy. How-
ever, plasma catecholamine and renin concentra-
tions were not determined in this investigation. The
mechanism for elevations in blood pressure after
repair of other congenital heart defects is not clear
but may be related to changes in renal blood flow
and/or delay in autoregulatory response to a
changed aortic blood flow.4
In this study, patients who underwent repair of
aortic coarctation had paradoxic hypertension, with
6 of 10 patients having systolic hypertension only.
This is consistent with the first phase of hyperten-
sion after coarctation repair.1, 8 Patients with coarc-
tation repair had a smaller decrease in their SBP
while receiving a higher esmolol dose than patients
undergoing repair of other congenital heart defects.
The higher doses required in patients with coarcta-
tion repair may be related to their increased norepi-
nephrine concentrations, increased TBC, or both.
Theoretically, with higher esmolol dosing, b1-block-
ing selectivity would be lost, leaving norepinephrine
to act on a-receptors unopposed. This would main-
Fig. 2. Bar graph comparing postoperative and final hemodynamic measurements. Systolic blood pressure
(SBP) was the only parameter significantly (p 5 0.000) different among preoperative, postoperative, and
final (1) measurements. HR and DBP indicate HR and diastolic blood pressure, respectively. *Indicates
significant difference (p # 0.005) from final measurement.
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tain or likely elevate systemic vascular resistance,
requiring a higher esmolol dose to reduce cardiac
output and lower blood pressure.
The mean esmolol dose required to normalize
blood pressure was 700 mg/kg/min. In a previous
investigation the mean dose to produce b-blockade
(defined as a 10% reduction in HR or MAP) was
535 mg/kg/min in 20 children undergoing indicated
cardiac electrophysiologic testing.20 This study also
found that the esmolol dosage required to control
hypertension was higher than that used in adults.
Esmolol doses used to control hypertension after
cardiac operations in adults are generally 100 to 300
mg/kg/min.9 The higher doses used in this study are
likely related to the degree of hypertension in these
patients (mean 13.3% above the 95th percentile for
age). Percent change in SBP was the only hemody-
namic parameter associated with esmolol dose. Fur-
ther reduction in SBP to progressively higher esmo-
lol blood concentrations and doses has been
reported in adults.11, 27 The hemodynamic measure-
ments obtained immediately after esmolol infusion
represent how rapidly the offset of HR and blood
pressure responses to esmolol begin to occur in most
patients.
The pharmacokinetics of esmolol have been re-
ported in children during cardiac catheterization,
where the elimination t1/2 was shorter (2 to 4
minutes)19, 21 and the dose requirements to produce
b-blockade were higher20 than those observed in
adults. The extremely short t1/2 of esmolol in chil-
dren (mean 2.7 minutes) was also observed in this
study. TBC of esmolol was higher in patients who
underwent repair of aortic coarctation than patients
undergoing repair of other congenital heart defects.
Esmolol is rapidly metabolized by red blood cell
esterases to an acid metabolite (ASL-8123) and
methanol.11 This would imply that red blood cell
esterase activity is enhanced in patients with aortic
coarctation. This enhanced TBC may explain the
observation that steady-state esmolol blood concen-
trations were not significantly different between the
coarctation and congenital heart defect groups.
Studies in adults and children have not consistently
reported an association between esmolol dose and
blood concentration at steady state.24, 19 This inves-
tigation found an association between dose and
concentration that supports a previous observation
in adults.8
In the pediatric intensive care setting, a cardiose-
lective b-blocker that is easily titratable with a rapid
onset and offset of action would be ideal, particu-
larly in patients at high risk for adverse effects.
Esmolol met these criteria in 19 of 20 children with
Fig. 3. Scatterplot showing the relationship between percent change in systolic blood pressure and esmolol
dose, as well as the predicted change in systolic blood pressure by dose (solid line) and 95% confidence
limits (dashed lines).
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significant to severe hypertension after cardiac op-
erations. This preliminary investigation demon-
strated that esmolol was a safe and effective agent
for the management of postoperative hypertension
in the population studied. As with any b-blocker,
caution should be used in patients with bradycardia,
poor left ventricular performance, high-degree
heart block, congenital heart defects with right-to-
left shunting, chronic airway disease (e.g., asthma),
diabetes, or other peripheral vascular diseases.
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